CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.
April 19th 2021
Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.
April 15th 2021
Lymphoma survivor Nina Luker talks about receiving a diagnosis at age 24 and how sharing her story with nearly 200,000 supporters on social media helped her find purpose.
April 6th 2021
Early findings show that glofitamab may be a safe and effective option for patients with pretreated, relapsed/refractory B-cell non-Hodgkin lymphoma.
March 25th 2021
In this episode of the “CURE® Talks Cancer” podcast, we spoke with a large B-cell lymphoma “alumni” who was diagnosed at 24 about what it was like to be the only young patient receiving infusions at her cancer center, and what led her to start a nonprofit organization to help others along their journey.
March 22nd 2021
For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.
March 11th 2021
This week on the “CURE® Talks Cancer” podcast, we spoke with lymphoma survivor Nina Luker about what it was like to receive a diagnosis at age 24, and how sharing her story with nearly 200,000 supporters on TikTok and Instagram led her to find purpose with the Lymphoma Research Foundation.
March 9th 2021
Nearly one year ago to the day, 24-year-old Nina Luker was completely blindsided by a diagnosis of non-Hodgkin lymphoma. But after powering through treatments in the thick of the COVID-19 pandemic, Luker is now cancer-free and offering advice to those who may be looking for ways to help their loved ones through difficult times of their own.
February 26th 2021
Throughout the winter, the FDA has continued to approve several new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.
February 20th 2021
As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment.
February 15th 2021
One patient with breast implant-associated anaplastic large cell lymphoma spoke out for herself throughout therapy — and encourages other patients do the same.
February 5th 2021
The Food and Drug Administration on Friday approved Breyanzi, a cell-based gene therapy, for the treatment of adults with certain types of large B-cell lymphoma.
December 8th 2020
This data, according to a resident physician at Brigham and Women’s Hospital, highlights the need for systematic mental health screening and management for individuals with blood cancers.
December 7th 2020
Patients with aggressive lymphomas experienced sharp increases in quality of life from time of diagnosis until one year later and continued to see improvements for almost a decade.
December 2nd 2020
Study results also determined that immune system status before treatment may predict outcomes post-treatment.
November 26th 2020
In this episode of the “CURE Talks Cancer” podcast, we spoke with a teenager who was diagnosed with Hodgkin lymphoma at the start of the COVID-19 pandemic. We talked about her cancer journey, what it was like to receive treatment during the pandemic, and more.